BRAF and neoplasm: Beyond the reduction of tumour burden and recurrence, neoadjuvant BRAF/MEK inhibition has the potential to facilitate organ-preserving surgeries, minimise functional and aesthetic impairment, and enhance long-term quality of life [35, 36].